ProMIS Neurosciences Inc. Common Shares (ON) (PMN) Dividend History

Company News

• Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

  The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.

  GlobeNewswire Inc.

  Featured Companies: ABBV ANVS DNLI PRTA
• ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

  ProMIS Neurosciences announced positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310, an antibody therapeutic targeting toxic misfolded proteins in Alzheimer's disease. The data showed a favorable safety profile, dose-dependent levels of PMN310 in the cerebrospinal fluid, and potential for target engagement in Alzheimer's patients.

  GlobeNewswire Inc.
• ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

  Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024

  GlobeNewswire Inc.
• Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

  Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA. Longeveron Inc. (NASDAQ: LGVN) surged 54% to $2.6350 following insider buys from multiple company executives. SuperCom Ltd. (NASDAQ: SPCB) shares gained 39.4% to $0.3849 after jumping around 18% on Friday. Piedmont Lithium Inc. (NYSE: PLL) shares gained 32.1% to $16.75 following a 5% decline on Friday. Snap One Holdings Corp. (NASDAQ: SNPO) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies. Organovo Holdings, Inc. (NASDAQ: ONVO) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. Kuke Music Holding Limited (NASDAQ: KUKE) jumped 27% to $2.7650. HUB Cyber Security Ltd. (NASDAQ: HUBC) gained 24% to $1.61 after gaining over 11% on Friday. Edgio, Inc. (NASDAQ: EGIO) gained 24% to $22.18. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ...

  Benzinga

  Featured Companies: ADIL AEYE BB BHVN CENX COCH CYN DXYZ EXTR HUBC IMCC INFA KAVL LGVN LOCL MNDR MPW NMRA NXPL OCX PLL PROK PSNY QTTB RARE RENT SES SNGX SPCB SPWR SRFM SWVL VERU
• Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

  U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also rose, gaining, 0.80% to 5,164.30. Check This Out: Best Buy, Box And 2 Other Stocks Insiders Are Selling   Leading and Lagging Sectors   Financial shares jumped by 1.5% on Friday. In trading on Friday, real estate shares rose by just 0.3%.   Top Headline   Goldman Sachs Group Inc. (NYSE: GS) reported better-than-expected first-quarter earnings on Monday. Goldman Sachs reported revenue of $14.21 billion for the first quarter of 2024, beating the consensus of $12.92 billion. The U.S. financial services giant reported EPS of $11.58, beating the consensus of $8.60.   Equities Trading UP   Soligenix, Inc. (NASDAQ: SNGX) shares shot up 98% to $0.7699 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and ...

  Benzinga

  Featured Companies: GS LGVN SNGX